{"id":56344,"date":"2023-04-28T15:07:22","date_gmt":"2023-04-28T13:07:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/"},"modified":"2023-04-28T15:07:22","modified_gmt":"2023-04-28T13:07:22","slug":"feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/","title":{"rendered":"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy"},"content":{"rendered":"
\n

MANHASSET, N.Y.–(BUSINESS WIRE)–There might be a new, non-pharmacological way to treat major mental health disorders like schizophrenia spectrum disorders and psychosis. Researchers at The Feinstein Institutes for Medical Research<\/a> have received a $3.4 million grant from Wellcome <\/a>to study repetitive <\/b>transcranial magnetic stimulation (rTMS) and its effects.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAlready approved by the U.S. Food and Drug Administration (FDA), rTMS is used to help treat people with depression and obsessive-compulsive disorder (OCD). Now, through Wellcome\u2019s support, Anil Malhotra, MD<\/a>, co-director and professor of the Feinstein Institutes\u2019 Institute of Behavioral Science<\/a>, will lead a new double-blind, randomized clinical trial that will study if rTMS improves social cognitive performance of people living with schizophrenia over the course of five years. This is the first time the Feinstein Institutes received funding from Wellcome, a London-based charitable foundation which focuses on funding health research.<\/p>\n

\n\u201cThere is no one silver bullet to treat mental health conditions. The success and effectiveness of rTMS have shown the potential to treat critical symptoms of schizophrenia,\u201d said Dr. Malhotra, who is also the vice chair for research with the Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell<\/a>. \u201cWith the support of Wellcome, we will get a better understanding of the effectiveness of rTMS to help those with cognitive effects of illness.\u201d<\/p>\n

\nWhen rTMS is used, an electromagnetic coil is placed against a patient\u2019s head. The coil delivers repetitive magnetic pulses that stimulate nerve cells in the brain that influence mood and depression. For effectiveness, the patient visits every day for several weeks.<\/p>\n

\nSchizophrenia affects approximately 24 million people worldwide, according to the World Health Organization<\/a>. It can affect how a person thinks, feels and behaves, and symptoms can vary in each individual person. Right now, there is no cure for schizophrenia, but it can be managed with medications. However, many people with schizophrenia are resistant to medication.<\/p>\n

\n\u201cResearch into cognitive mechanisms and disorders is a pivotal step towards improving outcomes in behavioral health,\u201d said Kevin J. Tracey, MD<\/a>, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. \u201cThrough this Wellcome support, Dr. Malhotra and his team are now well positioned to discover new strategies for those patients in need.\u201d<\/p>\n

\nWellcome supports science to solve urgent health challenges. It supports discovery research into life, health and wellbeing by taking on three worldwide health challenges: mental health, infectious disease, climate and health.<\/p>\n

\nThe announcement of Dr. Malhotra\u2019s grant comes from a larger funding effort that totals more than $16 million.<\/p>\n

\nAbout the Feinstein Institutes<\/i><\/b><\/p>\n

\nThe Feinstein Institutes for Medical Research<\/i><\/a> is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine \u2013 a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit<\/i> <\/i>http:\/\/feinstein.northwell.edu<\/i><\/a> <\/i>and follow us on<\/i> <\/i>LinkedIn<\/i><\/a>.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nJulianne Mosher Allen
\n
516-880-4824
\n
jmosherallen@northwell.edu<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MANHASSET, N.Y.–(BUSINESS WIRE)–There might be a new, non-pharmacological way to treat major mental health disorders like schizophrenia spectrum disorders and psychosis. Researchers at The Feinstein Institutes for Medical Research have received a $3.4 million grant from Wellcome to study repetitive transcranial magnetic stimulation (rTMS) and its effects. Already approved by the U.S. Food and Drug … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56344","6":"format-standard","7":"category-industry"},"yoast_head":"\nFeinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MANHASSET, N.Y.–(BUSINESS WIRE)–There might be a new, non-pharmacological way to treat major mental health disorders like schizophrenia spectrum disorders and psychosis. Researchers at The Feinstein Institutes for Medical Research have received a $3.4 million grant from Wellcome to study repetitive transcranial magnetic stimulation (rTMS) and its effects. Already approved by the U.S. Food and Drug ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-28T13:07:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230428005023\/en\/1776867\/21\/Anil_Malhotra_Wellcome_Trust.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy\",\"datePublished\":\"2023-04-28T13:07:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/\"},\"wordCount\":566,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230428005023\\\/en\\\/1776867\\\/21\\\/Anil_Malhotra_Wellcome_Trust.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/\",\"name\":\"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230428005023\\\/en\\\/1776867\\\/21\\\/Anil_Malhotra_Wellcome_Trust.jpg\",\"datePublished\":\"2023-04-28T13:07:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230428005023\\\/en\\\/1776867\\\/21\\\/Anil_Malhotra_Wellcome_Trust.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230428005023\\\/en\\\/1776867\\\/21\\\/Anil_Malhotra_Wellcome_Trust.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy - Pharma Trend","og_description":"MANHASSET, N.Y.–(BUSINESS WIRE)–There might be a new, non-pharmacological way to treat major mental health disorders like schizophrenia spectrum disorders and psychosis. Researchers at The Feinstein Institutes for Medical Research have received a $3.4 million grant from Wellcome to study repetitive transcranial magnetic stimulation (rTMS) and its effects. Already approved by the U.S. Food and Drug ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-28T13:07:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230428005023\/en\/1776867\/21\/Anil_Malhotra_Wellcome_Trust.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy","datePublished":"2023-04-28T13:07:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/"},"wordCount":566,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230428005023\/en\/1776867\/21\/Anil_Malhotra_Wellcome_Trust.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/","url":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/","name":"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230428005023\/en\/1776867\/21\/Anil_Malhotra_Wellcome_Trust.jpg","datePublished":"2023-04-28T13:07:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230428005023\/en\/1776867\/21\/Anil_Malhotra_Wellcome_Trust.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230428005023\/en\/1776867\/21\/Anil_Malhotra_Wellcome_Trust.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-awarded-3-4m-from-wellcome-to-study-schizophrenia-using-rtms-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Feinstein Institutes awarded $3.4M from Wellcome to study schizophrenia using rTMS therapy"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56344"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56344\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}